Search
Close this search box.

[:pb]New FDA oncology small molecule drugs approvals in 2020: Mechanism of action and clinical applications[:]

[:pb]Authors: Nogueira, T. C. M. ; De Souza, M. V. N.

Source: Bioorganic & Medicinal Chemistry, v. 46, p. 116340, 2021.

Publisher: ScienceDirect


Abstract

In 2020, fifty-three new drugs, including forty small-molecules (thirty-six new chemical entities and four new diagnostic agents) and thirteen biologic drugs were approved by the U.S. Food and Drug Administration (FDA). This year, small-molecules continue to play a role in innovative treatments representing around 75% of all drugs accepted by FDA. The dominant therapeutic area was oncology, accounting for twenty-three new approvals, including thirteen new chemical entities, four new diagnostic agents, and thirteen biologic drugs. Recognizing the importance of small-molecules on cancer treatment, this review aims to provide an overview regarding the clinical applications and mechanism of action of the thirteen new small-molecules (excluding new diagnostic agents) approved by FDA in 2020.


Keywords: cancer, small-molecule, drug, approvals

Document Type: Research Article

DOI: 10.1016/j.bmc.2021.116340

Publication date: 15 de setembro de 2021[:]

Compartilhar publicação

Facebook
Twitter
Email
LinkedIn
WhatsApp

Deixe seu comentário

Compartilhar

Sobre a SSCDT

Nosso grupo de pesquisa está situado em Farmanguinhos e atualmente é o maior laboratório farmacêutico oficial vinculado ao Ministério da Saúde. Farmanguinhos produz mais de um bilhão de medicamentos por ano para os programas estratégicos do Governo Federal, além de atender demandas emergenciais no Brasil e no exterior.

posts Recentes